[go: up one dir, main page]

DK1171578T3 - Farmaceutisk præparat, som omfatter NKT-celler, der er aktiveret af PIM, og anvendelse heraf i terapi - Google Patents

Farmaceutisk præparat, som omfatter NKT-celler, der er aktiveret af PIM, og anvendelse heraf i terapi

Info

Publication number
DK1171578T3
DK1171578T3 DK00920847T DK00920847T DK1171578T3 DK 1171578 T3 DK1171578 T3 DK 1171578T3 DK 00920847 T DK00920847 T DK 00920847T DK 00920847 T DK00920847 T DK 00920847T DK 1171578 T3 DK1171578 T3 DK 1171578T3
Authority
DK
Denmark
Prior art keywords
nkt
pharmaceutical composition
therapy
activated
cells
Prior art date
Application number
DK00920847T
Other languages
Danish (da)
English (en)
Inventor
Irina Apostolov
Gabriel Gachelin
Philippe Kourilsky
Yousuke Takahama
Original Assignee
Inst Nat Sante Rech Med
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pasteur Institut filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK1171578T3 publication Critical patent/DK1171578T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK00920847T 1999-04-19 2000-04-19 Farmaceutisk præparat, som omfatter NKT-celler, der er aktiveret af PIM, og anvendelse heraf i terapi DK1171578T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904897A FR2792205B1 (fr) 1999-04-19 1999-04-19 Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
PCT/FR2000/001029 WO2000063348A2 (fr) 1999-04-19 2000-04-19 Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie

Publications (1)

Publication Number Publication Date
DK1171578T3 true DK1171578T3 (da) 2003-10-13

Family

ID=9544579

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00920847T DK1171578T3 (da) 1999-04-19 2000-04-19 Farmaceutisk præparat, som omfatter NKT-celler, der er aktiveret af PIM, og anvendelse heraf i terapi

Country Status (12)

Country Link
US (2) US7052909B1 (pt)
EP (2) EP1346725A1 (pt)
JP (1) JP2003502284A (pt)
AT (1) ATE243252T1 (pt)
CA (1) CA2368029A1 (pt)
DE (1) DE60003417T2 (pt)
DK (1) DK1171578T3 (pt)
ES (1) ES2206221T3 (pt)
FR (1) FR2792205B1 (pt)
HK (1) HK1044795B (pt)
PT (1) PT1171578E (pt)
WO (1) WO2000063348A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505538A (en) * 2000-07-03 2004-12-24 Malaghan Inst Of Medical Res A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
FR2815641B1 (fr) * 2000-10-24 2002-12-27 Pasteur Institut Procede de criblage de molecules actives dans la prevention et le traitement des lesions atherosclereuses et ses applications
WO2004018002A2 (en) * 2002-08-23 2004-03-04 Gabriele Multhoff Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
WO2006009731A1 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Methods of using apo2l receptor agonists and nk cell activators
FR2908658B1 (fr) * 2006-11-20 2011-11-11 Centre Nat Rech Scient Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69840528D1 (de) * 1997-04-10 2009-03-19 Kyowa Hakko Kirin Co Ltd NKT-Zellenaktivatoren, die Alpha-Glycosylceramide enthalten
CA2302155A1 (en) * 1997-09-12 1999-03-18 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
AU3558899A (en) * 1998-04-13 1999-11-01 Brigham And Women's Hospital Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof

Also Published As

Publication number Publication date
FR2792205A1 (fr) 2000-10-20
PT1171578E (pt) 2003-11-28
CA2368029A1 (fr) 2000-10-26
DE60003417T2 (de) 2004-05-06
EP1171578B1 (fr) 2003-06-18
JP2003502284A (ja) 2003-01-21
WO2000063348A3 (fr) 2000-12-28
FR2792205B1 (fr) 2001-07-27
ATE243252T1 (de) 2003-07-15
US20060263376A1 (en) 2006-11-23
EP1171578A2 (fr) 2002-01-16
HK1044795A1 (en) 2002-11-01
HK1044795B (zh) 2003-10-10
WO2000063348A2 (fr) 2000-10-26
ES2206221T3 (es) 2004-05-16
DE60003417D1 (de) 2003-07-24
US7052909B1 (en) 2006-05-30
EP1346725A1 (fr) 2003-09-24

Similar Documents

Publication Publication Date Title
ATE344801T1 (de) Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
ES2041006T3 (es) La utilizacion de membranas asimetricas en dispositivos de suministro.
ATE357509T1 (de) Stimulierung von hämatopoietischen zellen im vitro
NO975716L (no) Imidazolforbindelser
NO20074455L (no) Innretning for preparering av en drikk fra en kapsel ved injisering av et trykksatt fluid, og kapselholder for bruk i innretningen
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
ATE526038T1 (de) Implantierbares medizinprodukt mit kontinuierlichem mittel-konzentrationsgefälle
DK2208784T3 (da) Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof
DE69838356D1 (de) Mit Zellen beschichtete Träger
ES2191192T3 (es) Tienopirimidinas.
GB2462561A (en) Ex vivo methods for testing organ system disruption
BR8802492A (pt) Composicao esterilizante e de alto grau desinfetante,inodora
MX9804817A (es) Solucion de preservacion.
DK1171578T3 (da) Farmaceutisk præparat, som omfatter NKT-celler, der er aktiveret af PIM, og anvendelse heraf i terapi
Lee et al. The efficacy of commercial tooth storage media for maintaining the viability of human periodontal ligament fibroblasts
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
FI962550A0 (fi) Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa
BR9806195A (pt) Composição edulcorante solúvel contendo fibras alimentares, sua preparação e uso para objetivo alimentar.
AR032933A1 (es) Compuestos que contienen creatina y creatinina
DK2089075T3 (da) Matrix-gel-transplantat uden celler
AR016473A1 (es) Preparado efervescente y procedimiento para su preparacion
AU2001290574A1 (en) Method and apparatus for measuring the hemoglobin concentration and/or hematocrit in whole blood using diffuse light
ATE527984T1 (de) 2-amino-5-ethylphenol enthaltendes mittel zum färben von keratinfasern
AR016930A1 (es) Composicion de tenido por oxidacion de las fibras queratinicas y procedimiento de tenido que utiliza esta composicion
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler